Health Condition 1: null- Lupus Nephritis
Conditions
Interventions
Intervention1: Multitargeted Therapy: MMF will be given in doses of 1 gm/day in 2 divided doses and TAC will be given at 0.1 mg/kg/day to target a trough level of 4-7 ng/ml.. MMF and TAC will be take
Sponsors
Director
Eligibility
Inclusion criteria
Inclusion criteria: 1. SLE diagnosis by ACR criteria 2. Lupus nephritis class III, IV, V, a combination of III+V or IV+V 3. Serum creatinine
Exclusion criteria
Exclusion criteria: 1. Severe proliferative lupus nephritis on Histopathologic Examination (eg. Crescents in >50% of the glomeruli) 2. Ongoing infection 3. Pregnant females 4. Low TLC count 5. Previously received immunosuppressive treatment 6. Patient not giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Decrease in proteinuria, defined as decrease in the urine protein/creatinine ratio to 3 in subjects with baseline nephrotic range proteinuria (â?¥3 urine protein/creatinine ratio) or decrease in the urine protein/creatinine ratio by â?¥50% in subjects with sub-nephrotic proteinuria (3 urine protein/creatinine ratio). This ratio is on the basis of 24 h urine collection 2.Stabilization of serum creatinine (i.e., a week 24 serum creatinine level ±25% of baseline) or improvement Timepoint: 24 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete renal remission (defined as a return to normal serum creatinine, proteinuria â?¤500mg/24hr and inactive urine sediment) and Adverse eventsTimepoint: 24 week | — |
Countries
India
Contacts
Public ContactKrishan Lal Gupta
Department of Nephrology
Outcome results
None listed